Hongene Biotech has received a grant from the Gates Foundation to develop patent-free cap analogs for use in mRNA vaccine production. The initiative is aimed at improving the availability of key raw materials for mRNA therapeutics and supporting global vaccine supply chains, particularly in low- and middle-income countries (LMICs).

The grant will fund the development and scale-up of critical capping reagents, essential for mRNA stability and translation, with a focus on accessibility and open deployment. Hongene said that resulting technologies and knowledge will be shared broadly and made available at affordable pricing for public sector and nonprofit manufacturers in LMICs.

Dr. David Butler, chief technology officer at Hongene, said: “High-quality raw materials are foundational to the reliability and scalability of mRNA manufacturing. This grant enables us to contribute our deep expertise in nucleotide chemistry to a global effort aimed at strengthening vaccine equity and readiness.”

The project incorporates provisions for open dissemination of results and technologies, and includes licensing measures to ensure that funded developments and essential background technology remain accessible to the public sector. Hongene emphasised that the initiative aligns with the Gates Foundation’s Global Access principles.

The grant supports the company’s broader goal of providing materials for RNA-based medicines, from synthesis to potential clinical use, while promoting equitable access to vaccines. No clinical or commercial products have yet resulted from this work; the announcement relates to early-stage development and capacity-building.

The funding reflects continued interest in ensuring mRNA vaccine supply chains are robust and accessible, particularly in LMICs, and highlights the role of open-access approaches in addressing global public health needs.